A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)

A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors

The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated.

Study Overview

• Status: Active, not recruiting
• Conditions: SCLC; Breast; Ovarian; Gastric Cancers
• Intervention / Treatment: Drug: Bevacizumab; Drug: Olaparib; Drug: MEDI4736

Detailed Description

This is a phase I/II open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK) and antitumor activity of MEDI4736 in combination with olaparib in patients with advanced solid tumors, selected based on a rationale for response to olaparib.

Patients will be poly (adenosine diphosphate-ribose) polymerase (PARP)-inhibitor and immunotherapy (IMT)-naïve (defined as no prior exposure to PARP inhibitors or IMT, including, but not limited to, other anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], anti-programmed cell death 1 [PD-1], anti-programmed death-ligand 1 [PD-L1] monoclonal antibodies, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).

The 4 initial stage cohorts (Modules 1 to 4) include patients with relapsed small cell lung cancer (SCLC), germline BRCA mutated (gBRCAm) metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer, gBRCAm platinum-sensitive relapsed ovarian cancer, and gastric cancer. The data cut-off occurred once all 4 Modules had reached last patient first visit (LPFV) + 2 years and all 4 cohorts had observed a median value for PFS.

Second stage cohorts (Modules 5 to 7) include patients with relapsed gBRCAm platinum-sensitive relapsed ovarian cancer and non gBRCAm platinum-sensitive relapsed ovarian cancer. The final data cut-off will be once Modules 6 and 7 have observed a median value for overall survival. At this timepoint, the clinical study database will close to new data.

• Study Type: Interventional
• Enrollment (Actual): 264
• Phase: Phase 2; Phase 1

Expanded Access

Approved for sale to the public. See expanded access record.

Contacts and Locations

Study Locations

• France
  • Bordeaux, France, 33076
    • Research Site
  • Caen, France, 14076
    • Research Site
  • Clermont-Ferrand, France, 63011
    • Research Site
  • Dijon, France, 21079
    • Research Site
  • Marseille, France, 13385
    • Research Site
  • Nantes, France, 44202
    • Research Site
  • Paris, France, 75014
    • Research Site
  • Pierre Benit Cedex, France, 69495
    • Research Site
  • Toulouse, France, 31059
    • Research Site
  • Villejuif, France, 94805
    • Research Site
• Israel
  • Haifa, Israel, 91096
    • Research Site
  • Jerusalem, Israel, 91031
    • Research Site
  • Petah Tikva, Israel, 49100
    • Research Site
  • Ramat Gan, Israel, 5265601
    • Research Site
  • Tel Aviv, Israel, 6423906
    • Research Site
• Netherlands
  • Amsterdam, Netherlands, 1066 CX
    • Research Site
  • Amsterdam, Netherlands, 1081 HV
    • Research Site
  • Maastricht, Netherlands, 6229 HX
    • Research Site
  • Nijmegen, Netherlands, 6525 GA
    • Research Site
  • Rotterdam, Netherlands, 3075 EA
    • Research Site
  • Utrecht, Netherlands, 3584 CX
    • Research Site
• South Korea
  • Goyang-si, South Korea, 10408
    • Research Site
  • Seongnam-si, South Korea, 13620
    • Research Site
  • Seoul, South Korea, 03080
    • Research Site
  • Seoul, South Korea, 03722
    • Research Site
  • Seoul, South Korea, 05505
    • Research Site
  • Seoul, South Korea, 06273
    • Research Site
  • Seoul, South Korea, 06591
    • Research Site
  • Seoul, South Korea, 135-710
    • Research Site
• Switzerland
  • Chur, Switzerland, CH-7000
    • Research Site
  • Lausanne, Switzerland, 1011
    • Research Site
• United Kingdom
  • Cambridge, United Kingdom, CB2 0QQ
    • Research Site
  • Dundee, United Kingdom, DD1 9SY
    • Research Site
  • Glasgow, United Kingdom, G12 0YN
    • Research Site
  • Greater London, United Kingdom, SW3 6JJ
    • Research Site
  • London, United Kingdom, NW1 2PG
    • Research Site
  • London, United Kingdom, SE1 9RY
    • Research Site
  • Manchester, United Kingdom, M20 4BX
    • Research Site
  • Newcastle upon Tyne, United Kingdom, NE7 7DN
    • Research Site
  • Sutton, United Kingdom, SM2 5PT
    • Research Site
• United States
  • Georgia
    • Newnan, Georgia, United States, 30265
      • Research Site
  • Maryland
    • Towson, Maryland, United States, 21204
      • Research Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Research Site
  • Michigan
    • Detroit, Michigan, United States, 48202
      • Research Site
  • Missouri
    • St Louis, Missouri, United States, 63110
      • Research Site
  • Ohio
    • Hilliard, Ohio, United States, 43026
      • Research Site
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 130 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion criteria:

• Patients must have histologically or cytologically confirmed progressive advanced or metastatic solid tumor of one of the following:

  • Platinum sensitive relapsed small cell lung cancer (module 1)
  • gBRCAm HER2-negative metastatic breast cancer (module 2)
  • gBRCAm ovarian cancer (modules 3 and 5)
  • Metastatic or relapsed Gastric cancer (adenocarcinoma) (module 4)
  • gBRCAm negative ovarian cancer (modules 6 and 7)
• At least one measurable lesion that can be accurately assessed at baseline by computed tomography (CT) (or magnetic resonance imaging [MRI] suitable for assessment as per RECIST 1.1. The baseline scan must be obtained within 28 days prior to the first dose of olaparib.
• Male or female patients, age ≥18 years (≥19 years for South Korea)
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Life expectancy ≥12 weeks
• Adequate organ and marrow function
• Ability to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation. Patients should not have gastrointestinal illnesses that would preclude the absorption of olaparib, which is an oral agent. For the gastric cancer cohort, patients with a full or partial gastrectomy will be permitted.
• Ability of patient to understand and the willingness to sign a written informed consent document prior to any protocol related procedures, including screening evaluations.

• Female patients must either:

  • Be of non-reproductive potential OR
  • Have a negative serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on Day 1, and agree to use contraception if they or their partner are of reproductive potential

Exclusion criteria

• Prior chemotherapy or other systemic anticancer therapy within 4 weeks prior to start of olaparib treatment, 6 weeks for nitrosoureas or mitomycin. Exceptions include: Anti-hormonal treatment for ER positive or PR positive breast cancer is allowed until 7 days prior to treatment with olaparib, exposure to an investigational agent within 30 days or 5 half-lives (whichever is the longer) prior to start of olaparib treatment is not allowed, prior receipt of biologics targeting T cell co-regulatory proteins and/or immune checkpoints is not allowed. Examples include MEDI4736 or other PD1 or PD-L1 or PD-L2 inhibitors or anti-CTLA4 therapy, previous treatment with a PARP inhibitor, is not allowed.
• Radiation therapy within 4 weeks prior to start of olaparib treatment (includes radiation targeting bone metastases) or radionuclide treatment within 6 weeks of treatment start.
• Current dependency on total parenteral nutrition or IV fluid hydration.
• Concomitant use of known strong cytochrome P450 (CYP) 3A (CYP3A) inhibitors or moderate CYP3A inhibitors. Concomitant use of known strong or moderate CYP3A inducers.
• Concomitant therapy with any other anticancer therapy or chronic use of systemic corticosteroids.
• Previous allogenic bone marrow transplant or double umbilical cord blood transplantation
• Whole blood transfusions in the last 120 days
• Patients with symptomatic or uncontrolled brain metastases.
• Patients being considered at poor medical risk due to a serious, uncontrolled medical disorder or non-malignant systemic disease.
• Any psychiatric disorder that prohibits obtaining informed consent
• Major surgery or significant traumatic injury within 2 weeks of run-in
• Immunocompromised patients
• QTc prolongation >470 msec or other significant ECG abnormality noted within 14 days of treatment
• Pregnant and breastfeeding women are excluded.
• Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
• Previous enrolment in the present study
• Participation in a clinical study within 28 days or 5 half-lives of the drug, whichever is longer.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm 1; Includes initial stage cohorts (modules 1 to 4): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 5 day 1	Drug: Olaparib; Olaparib; Drug: MEDI4736; MEDI4736
Experimental: Arm 2; Includes 2nd stage cohorts (modules 5 & 7): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 1 day 1	Drug: Olaparib; Olaparib; Drug: MEDI4736; MEDI4736
Experimental: Arm 3; Includes 2nd stage cohort (module 6): Olaparib twice daily starting on week 1 day 1 / MEDI4736 every 4 weeks starting on week 1 day 1 / Bevacizumab every 2 weeks starting on week 1 day 1	Drug: Bevacizumab; Bevacizumab; Other Names: Avastin; Drug: Olaparib; Olaparib; Drug: MEDI4736; MEDI4736

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Initial Stage Cohorts: Disease Control Rate (DCR) at Week 12	The DCR at 12 weeks was defined as the percentage of participants who had complete response (CR) + partial response (PR) + stable disease (SD) at 12 weeks. Participants demonstrated SD for a minimum interval of 11 weeks (minus 1 week to allow for an early assessment within the assessment window, i.e. 77 days) following the start of treatment. The DCR was determined using Investigator assessments according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).	RECIST performed at baseline, at 4 weeks after first dose of olaparib monotherapy and every 8 weeks +/-7 days thereafter. Assessed until DCO 14 Jun 2019.
Second Stage Cohort: Objective Response Rate (ORR)	The ORR (based on RECIST 1.1 as assessed by the Investigator) was defined as the percentage of participants with at least 1 visit response of CR or PR prior to PD or last evaluable assessment in the absence of progression. The 95% confidence interval (CI) were calculated using Exact Clopper-Pearson confidence limits for the binomial proportion.	RECIST performed at baseline, and every 8 weeks +/-7 days thereafter. Assessed until 17 Sep 2021.
Second Stage Cohorts: DCR at Week 24	The DCR at 24 weeks was defined as the percentage of participants who had CR + PR + SD at 24 weeks. Participants demonstrated SD for a minimum interval of 23 weeks (minus 1 week to allow for an early assessment within the assessment window, i.e. 161 days) following the start of treatment. The DCR was determined using Investigator assessments according to RECIST v1.1.	RECIST performed at baseline, and every 8 weeks +/-7 days thereafter. Assessed until 17 Sep 2021.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Second Stage Expansion Cohort: DCR at Week 24	The DCR at 24 weeks was defined as the percentage of participants who had CR + PR + SD at 24 weeks. Participants demonstrated SD for a minimum interval of 23 weeks (minus 1 week to allow for an early assessment within the assessment window, i.e. 161 days) following the start of treatment. The DCR was determined using Investigator assessments according to RECIST v1.1.	RECIST performed at baseline, and every 8 weeks +/-7 days thereafter. Assessed until 17 Sep 2021.
Initial Stage Cohorts: DCR at Week 28	The DCR at 28 weeks was defined as the percentage of participants who had CR + PR + SD at 28 weeks. Participants demonstrated SD for a minimum interval of 27 weeks (minus 1 week to allow for an early assessment within the assessment window, i.e. 189 days) following the start of treatment. The DCR was determined using Investigator assessments according to RECIST v1.1.	RECIST performed at baseline, at 4 weeks after first dose of olaparib monotherapy and every 8 weeks +/-7 days thereafter. Assessed until DCO 14 Jun 2019.
Second Stage Cohorts: DCR at Week 56	The DCR at 56 weeks was defined as the percentage of participants who had CR + PR + SD at 56 weeks. Participants demonstrated SD for a minimum interval of 55 weeks (minus 1 week to allow for an early assessment within the assessment window, i.e. 385 days) following the start of treatment. The DCR was determined using Investigator assessments according to RECIST v1.1.	RECIST performed at baseline, and every 8 weeks +/-7 days thereafter. Assessed until 17 Sep 2021.
Initial and Second Stage Cohorts: ORR	The ORR (based on RECIST 1.1 as assessed by the Investigator) was defined as the percentage of participants with at least 1 visit response of CR or PR prior to PD or last evaluable assessment in the absence of progression. The 95% CI were calculated using Exact Clopper-Pearson confidence limits for the binomial proportion.	RECIST performed at baseline, at 4 weeks after first dose of olaparib monotherapy (for initial stage cohort only) and every 8 weeks +/-7 days thereafter. Assessed until DCO 14 Jun 2019 and 17 Sep 2021 for initial and second stage cohorts, respectively
Initial and Second Stage Cohorts: Duration of Response (DoR)	The DoR (based on RECIST 1.1 as assessed by the Investigator) was defined as the time from the date of first documented response until date of documented progression or death in the absence of PD. The DoR was calculated using Kaplan-Meier technique.	RECIST performed at baseline, at 4 weeks after first dose of olaparib monotherapy (for initial stage cohort only) and every 8 weeks +/-7 days thereafter. Assessed until DCO 14 Jun 2019 and 17 Sep 2021 for initial and second stage cohorts, respectively
Initial and Second Stage Cohorts: Progression-Free Survival (PFS)	The PFS (based on RECIST 1.1 as assessed by the Investigator) was defined as the time from start of study treatment (Day 1; start of olaparib monotherapy for initial stage cohorts) until the date of objective PD or death (by any cause in the absence of disease progression) regardless of whether the patient withdraws from therapy or receives another anticancer therapy prior to disease progression. The PFS was calculated using Kaplan-Meier technique.	RECIST performed at baseline, at 4 weeks after first dose of olaparib monotherapy (for initial stage cohort only) and every 8 weeks +/-7 days thereafter. Assessed until DCO 14 Jun 2019 and 17 Sep 2021 for initial and second stage cohorts, respectively
Initial Stage Cohorts: Percentage Change From Baseline in Target Tumor Size at Weeks 12 and 28	The percentage change in target tumor size at each timepoint (based on RECIST 1.1 target lesion measurements) was obtained for each participant taking the difference between the sum of the target lesions at each timepoint and the sum of the target lesions at baseline divided by the sum of the target lesions at baseline times 100. Baseline was defined as the last evaluable assessment prior to starting olaparib treatment.	Baseline (Day 1) and Weeks 12 and 28. Assessed until DCO 14 Jun 2019
Second Stage Cohorts: Percentage Change From Baseline in Target Tumor Size at Weeks 24 and 56	The percentage change in target tumor size at each timepoint (based on RECIST 1.1 target lesion measurements) was obtained for each participant taking the difference between the sum of the target lesions at each timepoint and the sum of the target lesions at baseline divided by the sum of the target lesions at baseline times 100. Baseline was defined as the last assessment prior to Cycle 1 Day 1.	Baseline (Day 1) and Weeks 24 and 56. Assessed until DCO 17 Sep 2021
Initial and Second Stage Cohorts: Best Percentage Change From Baseline in Target Tumor Size	The best percentage change from baseline in target tumor size was based on RECIST 1.1 target lesion measurements taken at each RECIST 1.1 assessment. All measurements until PD or the last evaluable assessment in the absence of PD was included in the calculation. Baseline was defined as the last evaluable assessment prior to starting olaparib treatment for initial stage cohorts. Baseline was defined as the last assessment prior to Cycle 1 Day 1 for second stage cohorts.	From baseline (Day 1) until confirmed PD/death. Assessed until DCO 14 Jun 2019 and 17 Sep 2021 for initial and second stage cohorts, respectively
Initial and Second Stage Cohorts: Time to Study Treatment Discontinuation or Death (TDT)	The TDT was defined as the time from start of study treatment (Day 1; start of olaparib monotherapy for initial stage cohorts) to the earlier of the date of study treatment discontinuation or death. The TDT was calculated using the Kaplan-Meier technique.	From baseline (Day 1) until treatment discontinuation/death. Assessed until DCO 14 Jun 2019 and 17 Sep 2021 for initial and second stage cohorts, respectively
Initial and Second Stage Cohorts: OS	The OS was defined as the time from the start of study treatment (Day 1; start of olaparib monotherapy for initial stage cohorts) until death due to any cause. The OS was calculated using the Kaplan-Meier technique.	From baseline (Day 1) until death from any cause. Assessed until DCO 14 Jun 2019 for initial stage cohorts except for ovarian cancer cohort and DCO 17 Sep 2021 for initial stage ovarian cancer cohort and second stage cohorts
Initial and Second Stage Cohorts: Serum Concentrations of MEDI4736	Blood samples were collected to determine the serum concentration of MEDI4736.	Pre-dose and within 10 minutes of end of infusion on Days 1, 85 and 113; Pre-dose on Days 29, 57 and 169; and 90 days post last dose of MEDI4736. Assessed until DCO 14 Jun 2019 and 17 Sep 2021 for initial and second stage cohorts, respectively
Initial and Second Stage Cohorts: Serum Concentrations of Olaparib	Blood samples were collected to determine the serum concentration of olaparib.	Pre-dose and 0.5-1 hour postdose on Days 1 and 22 of monotherapy; Pre-dose and 0.5-1, 1-3, 3-6 and 6-12 hours postdose on Day 15 of combination therapy. Assessed until DCO 14 Jun 2019 and 17 Sep 2021 for initial and second stage cohorts, respectively
Second Stage Cohort: Serum Concentrations of Bevacizumab	Blood samples were collected to determine the serum concentration of bevacizumab.	Pre-dose and within 10 minutes of end of infusion on Days 1 and 85; Pre-dose on Days 29 and 169; and 90 days post last dose of bevacizumab. Assessed until DCO 17 Sep 2021
Initial and Second Stage Cohorts: Number of Participants With Anti-Drug Antibody (ADA) Response to MEDI4736	Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for MEDI4736 using validated assays. ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA incidence (treatment-emergent ADA) was defined as the sum of both treatment-induced (post-baseline ADA positive only) and treatment-boosted ADA. Treatment-boosted ADA was defined as baseline ADA titer that was boosted to 4-fold or higher following drug administration. Persistently positive was defined as positive at >=2 post-baseline assessments (with >=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.	Pre-dose on Days 1, 15, 57, 85, 113 and 169; and 90 days post-last dose of MEDI4736. Assessed until DCO 14 Jun 2019 and 17 Sep 2021 for initial and second stage cohorts, respectively

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tumor genetics	To determine presence of homologous recombination repair (BRCA1, BRCA2) ATM and overall mutation burden (All modules)	At Screening
Pharmacodynamics: Paired tumor biopsies	Tumor samples will be analyzed for biomarkers including CD8 expressing T cells, PD-L1 expression, measures of T-cell repertoire, gene expression and markers associated with immunogenic cell death (All modules)	Olaparib Run-In Treatment week 1 day1. Each cycle = 28 days in combination of treatment. Day 1 of cycle 1; Day 1 of Cycle 2
Pharmacodynamics: whole blood for gene expression (PAXgene-RNA)	angiogenic predictive biomarkers: may include but is not limited to tumor gene expression profiling, tumor vascular morphology/microvessel density and peripheral soluble markers of angiogenesis eg, VEGF, Ang-1 (Modules 5, 6 and 7)	Olaparib Run-In Treatment week 1 day 1. Each cycle = 28 days in combination of treatment. Day 1 of cycle 1; Day 1 of Cycle 2; Day 1 of Cycle 3
Pharmacodynamics: circulating soluble factors in the plasma	The concentrations of a panel of cytokines and chemokines will be assessed. (All modules)	Olaparib Run-In Treatment week 1 day 1. Each cycle = 28 days in combination of treatment. Day 1 of cycle 1; Day 1 of Cycle 2; Day 1 of Cycle 3; Day 1 of Cycle 6
Pharmacodynamics: whole blood for immunophenotyping	Whole blood samples will be collected for flow cytometry-based immunophenotyping of circulating lymphocytes (All modules)	Screening. Olaparib Run-In Treatment week 1 day 1. Each cycle = 28 days in combination of treatment. Day 1 of cycle 1; Day 15 of Cycle 1; Day 1 of Cycle 2; Day 1 of Cycle 3
Pharmacodynamics: peripheral blood mononuclear cells	Whole blood samples will be collected for preparation of PBMCs and storage for potential downstream analyses. (All modules)	Olaparib Run-In treatment week 1 day 1. Olaparib Run-In treatment week 3 day 1. Each cycle = 28 days in combination of treatment. Day 1 of cycle 1; Day 15 of Cycle 1; Day 1 of Cycle 2; Day 1 of Cycle 3
Pharmacogenetics	Optional: patient consent required to collect and store DNA from blood (according to each country's local and ethical procedures) for future exploratory research into genes/genetic variation that may influence response (ie, distribution, safety, tolerability and efficacy) to study treatments and or susceptibility to disease (Optional)	Olaparib Run-In treatment week 1 day 1
Characterize the pharmacodynamics profile of bevacizumab: Efficacy of bevacizumab in combination with olaparib and MEDI4736 compared to olaparib and MEDI4736 alone	Evaluation of plasma samples collected before treatment, longitudinally and upon progression including, but not limited to, VEGF (Modules 6 and 7)	At baseline and upon progression
Angiogenic predictive biomarkers: may include but is not limited to tumor gene expression profiling, tumor vascular morphology/microvessel density and peripheral soluble markers of angiogenesis eg, VEGF, Ang-1	To evaluate baseline measures and changes induced by olaparib alone and in combination with MEDI4736±bevacizumab, in peripheral blood, archival tumor, and tumor biopsies (frozen and fixed cores) (Modules 6 and 7)	Since Screening and untill disease progression.

Collaborators and Investigators

• Sponsor: AstraZeneca
• Collaborators: IQVIA Pty Ltd
• Investigators: Principal Investigator: Susan Domchek, MD, Abramson Cancer Center, University of Pennsylvania

Publications and helpful links

General Publications

• Staniszewska AD, Armenia J, King M, Michaloglou C, Reddy A, Singh M, San Martin M, Prickett L, Wilson Z, Proia T, Russell D, Thomas M, Delpuech O, O'Connor MJ, Leo E, Angell H, Valge-Archer V. PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors. Oncoimmunology. 2022 Jun 18;11(1):2083755. doi: 10.1080/2162402X.2022.2083755. eCollection 2022.
• Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, Alexandre J, You B, Bastian S, Krebs MG, Wang D, Waqar SN, Lanasa M, Rhee J, Gao H, Rocher-Ros V, Jones EV, Gulati S, Coenen-Stass A, Kozarewa I, Lai Z, Angell HK, Opincar L, Herbolsheimer P, Kaufman B. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020 Sep;21(9):1155-1164. doi: 10.1016/S1470-2045(20)30324-7. Epub 2020 Aug 6.
• Drew Y, Kim JW, Penson RT, O'Malley DM, Parkinson C, Roxburgh P, Plummer R, Im SA, Imbimbo M, Ferguson M, Rosengarten O, Steeghs N, Kim MH, Gal-Yam E, Tsoref D, Kim JH, You B, De Jonge M, Lalisang R, Gort E, Bastian S, Meyer K, Feeney L, Baker N, Ah-See ML, Domchek SM, Banerjee S; MEDIOLA Investigators. Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naive Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clin Cancer Res. 2024 Jan 5;30(1):50-62. doi: 10.1158/1078-0432.CCR-23-2249.

Helpful Links

• Related Info
• Related Info
• Related Info

Study record dates

Study Major Dates

• Study Start (Actual): March 17, 2016
• Primary Completion (Actual): September 17, 2021
• Study Completion (Estimated): September 17, 2026

Study Registration Dates

• First Submitted: March 17, 2016
• First Submitted That Met QC Criteria: April 6, 2016
• First Posted (Estimated): April 12, 2016

Study Record Updates

• Last Update Posted (Actual): April 20, 2026
• Last Update Submitted That Met QC Criteria: April 17, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Bevacizumab; Gastric Cancer; Breast cancer; Ovarian cancer; Olaparib; Small Cell Lung Cancer; MEDI4736; PDL-1; MEDIOLA; Phase I/II, Adults
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Endocrine System Diseases; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Respiratory Tract Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases; Genital Diseases, Female; Lung Diseases; Endocrine Gland Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Neoplasms, Female; Gonadal Disorders; Skin Diseases; Breast Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Skin and Connective Tissue Diseases; Stomach Neoplasms; Ovarian Neoplasms; Breast Neoplasms; Small Cell Lung Carcinoma; Amino Acids, Peptides, and Proteins; Proteins; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Serum Globulins; Globulins; Bevacizumab; durvalumab; olaparib
• Other Study ID Numbers: D081KC00001; 2015-004005-16 (EudraCT Number)